

Application News

Liquid Chromatograph Mass Spectrometer LCMS-9050

Analysis of mRNA 5' Cap Structure Using a Quadrupole Time-of-Flight Mass Spectrometer

Junna Nakazono

User Benefits

- ◆ The LCMS-9050 quadrupole time-of-flight mass spectrometer and the LabSolutions Insight™ Biologics analysis software enable characterization of the 5' cap structure of mRNA.
- ◆ The software enables simple confirmation of the fragment coverage of nucleic acids and their impurities.
- ◆ The software enables analysis of modifications and impurities that are set by the user.

■ Introduction

There has been increased attention on the new drug discovery modality of mRNA because of its efficacy in COVID-19 vaccines, and its applications for vaccines and other pharmaceuticals are expected to grow. Currently authorized mRNA vaccines are synthesized using *in vitro* transcription to add the Cap-1 structure (m7GpppRm-) on the 5' end. This modification contributes to mRNA recognition, better efficiency of translation, and stability of mRNA in cell, making 5' cap structure analysis an important element of mRNA quality controls.

This Application News presents a study of mRNA 5' cap structure using the LCMS-9050 quadrupole time-of-flight mass spectrometer and LabSolutions Insight Biologics analysis software.

■ Samples

Given that mRNA is a large molecule, LC/MS analysis is typically done by analyzing fragments generated by cleavage enzyme reactions. In this study, the model sample consisted of Cap-1 structure mRNA with 36 bases (Cap-1 groups) obtained by *in vitro* transcription using plasmid DNA as a template. The 5' cap modified unreacted RNA (pppR-) was also provided for analysis as an impurity.

■ Analytical Conditions

Analysis was performed using the Nexera™ XS inert and LCMS-9050 systems in Data Dependent Acquisition (DDA) mode. The analytical conditions are shown in Table 1.

Table 1 Analytical Conditions

UHPLC (Nexera XS inert)	
Column:	Shim-pack Scepter™ Claris C18-120* (150 mm × 2.1 mm I.D., 1.9 μm)
Mobile Phase A:	95 mM HFIP, 5 mM DIPEA - water
Mobile Phase B:	70 mM HFIP, 5 mM DIPEA, 65% acetonitrile - water
Gradient Program:	B Conc. 5% (0-2 min) – 25% (22 min) – 90% (23-24 min) – 5% (24.1-30 min)
Flowrate:	0.3 mL/min
Column Temp.:	60 °C
Injection Volume:	5 μL
MS (LCMS-9050)	
Ionization:	ESI negative
Mode:	MS <i>m/z</i> 550-2500, MS/MS (DDA) <i>m/z</i> 100-2500
Nebulizing Gas Flow:	3.0 L/min
Drying Gas Flow:	10.0 L/min
Heating Gas Flow:	10.0 L/min
Interface Temp.:	250 °C
DL Temp.:	250 °C
Block Heater Temp.:	400 °C

■ Setting the Analysis Parameters

LabSolutions Insight Biologics software is used to analyze nucleic acids and their impurities. First, the user creates a nucleic acid sequence in the parameter configuration window using the software presets for nucleobases, linkers, ribose, and modifications. Nucleobases, linkers, ribose, and base modifications can be added and removed in each tab as required. Once a sequence is entered, the software displays the molecular formula, monoisotopic mass, and structural formula (Fig. 1).




Fig. 1 Parameter Configuration Window

The Target Modifications tab is also used to select the anticipated impurities. In addition to impurities, such as different strand lengths, missing nucleobases, depurination/depyrimidination, deamination, and protecting groups, as well as adduct ions and unknown modifying groups, the software can also search for molecular changes added by the user. To enable detection of the 5' cap modified unreacted group as the impurity in this study, "5' uncapped" was added as the target modification (Fig. 2).




Fig. 2 Setting the Target Modification

■ Identifying Cap-1 and Unreacted Groups

Fig. 3 shows the component chromatogram of analyzed samples obtained by mixing Cap-1 group and the unreacted group by 0.5 µg each. The mass chromatogram is displayed as a component chromatogram, based on MS1 spectra and by combining signals from different valences and isotopes. Fig. 4 shows a result of multivalent ion analysis. Metal adducts were

also detected. Moreover, longmers with an additional cytidine (C) (N+1 groups) were detected in the Cap-1 group and the unreacted group at ratios of 6.6 and 7.9%, respectively (Fig. 5). These groups were putatively identified as secondary reaction products generated by *in vitro* transcription.




Fig. 3 Component Chromatograms of the Cap-1 Group and the Unreacted Group Mixture
FLP (A1:C36) indicates the Cap-1 group, and FLP (A1:C36)[uncap] indicates the unreacted group.




Fig. 4 Results of Multivalent Ion Analysis
Top: Deconvoluted mass spectrum; Center: Mass spectrum; Bottom: Identification results




Fig. 5 Results of N+1 Group Identification in Cap-1 Group and Unreacted Groups Mixture
N-pCr (A1:C36) and N-pCr (A1:C36)[uncap] indicate the N+1 groups for the Cap-1 group and the unreacted group, respectively.

Sequence Identification

Fig. 6 shows the results of sequence coverage in the unreacted group, based on fragment ion information in MS/MS spectra. Upon identification of the selected target modification, the position of the modification is displayed in red. Identification of

the N+1 group in the unreacted group also revealed characteristic fragment ions, including 3' side C additions (Fig. 7). The detection of different strand lengths is indicated by the red inverse triangles.




Fig. 6 Sequence Coverage of the Unreacted Group




Fig. 7 Sequence Coverage of the N+1 Group in the Unreacted Group

Impurity Quantitation

Analysis of the samples, which were obtained by spiking the Cap-1 group with the unreacted group at concentrations of 0, 5, and 10%(w/w), was performed with the LabSolutions Insight Biologics software. The analysis showed the areas value had good linearity ($R^2 > 0.99$) (Fig. 8).




Fig. 8 Linearity of Unreacted Group (Impurity) Area Values

Conclusion

In this study, molecular weight identification and sequence analysis of 5' cap modified mRNA was performed using the high-resolution LCMS-9050 mass spectrometer and LabSolutions Insight Biologics software. This instrument and software also enabled detection and sequence identification of impurities (N+1 group), in addition to detecting the Cap-1 and unreacted groups. LabSolutions Insight Biologics software simplifies the identification of modifications and deletions and additions with different strand lengths via the sequence coverage window.

The software also yielded area values of impurity with good linearity in the samples obtained by spiking the Cap-1 group with the unreacted group at concentrations of 0, 5, and 10%.

Related Applications

1. An Oligonucleotide Impurity Analysis Workflow Using LabSolutions Insight™ Biologics Software
[Application News No. 01-00595A-EN](#)
2. Simple Analysis of Impurities in Oligonucleotide Therapeutics Using a Single Quadrupole Mass Spectrometer
[Application News No. 01-00656-EN](#)

LabSolutions Insight, Nexera, and Shim-pack Scepter are trademarks of Shimadzu Corporation or its affiliated companies in Japan and other countries.



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. See <http://www.shimadzu.com/about/trademarks/index.html> for details.

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®".

Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

01-00733-EN

First Edition: Jun. 2024

➤ Please fill out the survey

Related Products

Some products may be updated to newer models.



➤ **Nexera XS inert**
Ultra High Performance Liquid Chromatograph



➤ **LCMS-9050**
Quadrupole Time-of-Flight Liquid Chromatograph Mass Spectrometer



Shim-pack Scepter LC Columns
➤ **Shim-pack Scepter LC Columns**
HPLC Column

Related Solutions

➤ **Pharmaceutical and Biopharmaceutical**

➤ **Oligonucleotide Therapeutics**

➤ **Cap Structural Analysis**

➤ **mRNA Therapeutics and Vaccines**

➤ **Price Inquiry**

➤ **Product Inquiry**

➤ **Technical Service / Support Inquiry**

➤ **Other Inquiry**